Sunday, April 17, 2011

Autism and Vaccines Researcher for CDC, Indicted for Fraud and Money-Laundering - CNBC

ATLANTA, April 14, 2011 /PRNewswire via COMTEX/ -- SafeMinds demands long-overdue independent review of vaccine/autism research for data manipulation and conflicts of interest. Vaccine safety remains questionable.

Poul Thorsen, the principal coordinator of multiple studies funded by the Centers for Disease Control and Prevention (CDC) used to deny a vaccine/autism link was indicted on April 13th on 13 counts of fraud and 9 counts of money-laundering. The charges relate to funding for work he conducted for the CDC, which claimed to disprove associations between the mercury-based vaccine preservative, thimerosal, and increased rates of autism.

SafeMinds first voiced concerns in 2003 regarding a series of epidemiology studies out of Denmark and under the jurisdiction of Thorsen that provided the basis for the Institute of Medicine's claim that there was no association between thimerosal and autism. That claim has been responsible for the continued unsafe use of mercury in influenza vaccines in the United States and infant vaccines around the world.

"The quality of this epidemiological research has always been questionable," states Sallie Bernard, SafeMinds president. "Many biological studies support a link between mercury and autism, but these Danish studies have been used to suppress further research into thimerosal. With clear evidence of Dr. Thorsen's lack of ethics, it is imperative to reopen this investigation." From August to October of 2003, three articles on the autism-mercury controversy were published in close succession, all of which used data from a Danish registry for psychiatric research to assess the relationship between autism trends and the use of thimerosal. SafeMinds accessed the registry at the time and reported that a large percentage of diagnosed autism cases are lost from the Danish registry each year and that most of those lost cases were older children.

Since the studies were based on finding fewer older thimerosal-exposed children than younger unexposed children, the validity of their conclusion exonerating thimerosal in autism was questionable and likely a result of missing records rather than true lower incidence rates among the exposed group.

In addition, internal emails obtained via FOIA document discussion between the Danish researchers and Thornsen which acknowledge that the studies did not include the latest data from 2001 where the incidence and prevalence of autism was declining which would be supportive of a vaccine connection.



No comments: